Acumen Selling General Administrative from 2010 to 2025
| ABOS Stock | USD 1.32 0.02 1.49% |
Selling General Administrative | First Reported 2010-12-31 | Previous Quarter 21.6 M | Current Value 22.7 M | Quarterly Volatility 8.2 M |
Check Acumen Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Acumen Pharmaceuticals' main balance sheet or income statement drivers, such as Net Interest Income of 9.9 M, Interest Income of 9.9 M or Depreciation And Amortization of 157.3 K, as well as many indicators such as Price To Sales Ratio of 415, Dividend Yield of 0.0 or PTB Ratio of 0.66. Acumen financial statements analysis is a perfect complement when working with Acumen Pharmaceuticals Valuation or Volatility modules.
Acumen | Selling General Administrative |
Latest Acumen Pharmaceuticals' Selling General Administrative Growth Pattern
Below is the plot of the Selling General Administrative of Acumen Pharmaceuticals over the last few years. It is Acumen Pharmaceuticals' Selling General Administrative historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Acumen Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Selling General Administrative | 10 Years Trend |
|
Selling General Administrative |
| Timeline |
Acumen Selling General Administrative Regression Statistics
| Arithmetic Mean | 5,872,134 | |
| Geometric Mean | 2,282,661 | |
| Coefficient Of Variation | 140.19 | |
| Mean Deviation | 6,747,810 | |
| Median | 926,000 | |
| Standard Deviation | 8,232,084 | |
| Sample Variance | 67.8T | |
| Range | 21.8M | |
| R-Value | 0.81 | |
| Mean Square Error | 25.5T | |
| R-Squared | 0.65 | |
| Significance | 0.0002 | |
| Slope | 1,393,071 | |
| Total Sum of Squares | 1016.5T |
Acumen Selling General Administrative History
About Acumen Pharmaceuticals Financial Statements
Acumen Pharmaceuticals shareholders use historical fundamental indicators, such as Selling General Administrative, to determine how well the company is positioned to perform in the future. Although Acumen Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Acumen Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Acumen Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Selling General Administrative | 21.6 M | 22.7 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Acumen Stock Analysis
When running Acumen Pharmaceuticals' price analysis, check to measure Acumen Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acumen Pharmaceuticals is operating at the current time. Most of Acumen Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acumen Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acumen Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acumen Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.